STOCK TITAN

MacroGenics (MGNX) Financials

MGNX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $128.9M +39.4% YoY
Net Income -$51.5M n/m YoY
EPS (Diluted) -$0.81 n/m YoY
Free Cash Flow -$41.3M n/m YoY
Market Cap $125.3M as of Nov 20, 2026
Price / Sales 1.0x on $128.9M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 5.0x on $25.2M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the MGNX SEC filings page.

MacroGenics, Inc. (MGNX) reported $128.9M in revenue over the twelve months to Sep 30, 2026, up 39.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MGNX FY2025

MacroGenics remains development-led: spending nearly matches revenue, losses persist, and liabilities now absorb most of its assets.

Cash conversion is closely tracking reported losses: the company burned $81.0M in operating cash and $83.0M after capital spending in FY2025, leaving little gap for investment to explain. Meanwhile, R&D consumed 98.4% of revenue, indicating that ongoing development spending—not heavy physical expansion—is the central cash requirement.

The operating margin improved by 25.0 pp as SG&A fell 44.9% from FY2024, showing expense reduction rather than sales growth drove the operating improvement. Revenue fell 0.3%, yet the company still posted a net loss of $74.6M, so margin improvement did not translate into positive earnings.

The capital structure has shifted sharply toward liabilities: liabilities reached 78.4% of assets in FY2025, up from 55.6% in FY2024. Equity fell to $55.6M, even as the current ratio stood at 5.1x, making short-term coverage look less strained than the longer-term balance-sheet position.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 59 / 100
Financial Health Score 59/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of MacroGenics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
28

MacroGenics, Inc. held $57.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $81.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and MacroGenics, Inc. scores 28/100 among other emerging companies.

Dilution
82

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. MacroGenics, Inc. scores 82/100 on it among other emerging companies.

R&D Intensity
86

MacroGenics, Inc. spent $147.2M on research and development in fiscal year 2025, which was 66.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and MacroGenics, Inc. scores 86/100 among other emerging companies.

Revenue Progress
81

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. MacroGenics, Inc. scores 81/100 on it among other emerging companies.

Burn Trend
47

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. MacroGenics, Inc. scores 47/100 on it among other emerging companies.

Balance Sheet
32

MacroGenics, Inc.'s cash, cash equivalents and investments came to $57.2M at the end of fiscal year 2025, against $201.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and MacroGenics, Inc. scores 32/100 among other emerging companies.

Altman Z-Score Distress
-5.94

MacroGenics, Inc. scores -5.94, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.2B against total assets of $256.8M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

MacroGenics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.

Earnings Quality No Cash Backing
N/A

MacroGenics, Inc. reported a net loss of $74.6M while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

MacroGenics, Inc. reported an operating loss of $72.8M against $8.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$18.7M
YoY-64.8%
QoQ-43.1%
5Y CAGR+3.6%
10Y CAGR+19.1%

MacroGenics, Inc. generated $18.7M in revenue in Q3 2026. This represents a decrease of 64.8% from the same quarter a year earlier. Against the prior quarter it is down 43.1%.

EBITDA
-$20.1M
YoY-265.1%
QoQn/m
5Y CAGRn/m

MacroGenics, Inc.'s EBITDA was -$20.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 265.1% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$20.1M
YoY-219.3%
QoQ-202.9%
5Y CAGRn/m
10Y CAGRn/m

MacroGenics, Inc. reported a net loss of $20.1M in Q3 2026. This represents a decrease of 219.3% from the same quarter a year earlier. Against the prior quarter it is down 202.9%.

EPS (Diluted)
-$0.32
YoY-218.5%
QoQ-203.2%
5Y CAGRn/m

MacroGenics, Inc. earned -$0.32 per diluted share (EPS) in Q3 2026. This represents a decrease of 218.5% from the same quarter a year earlier. Against the prior quarter it is down 203.2%.

Cash & Balance Sheet

Free Cash Flow
-$6.4M
YoYn/m
QoQn/m
5Y CAGRn/m

MacroGenics, Inc. recorded an outflow of $6.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$49.0M
YoY-38.8%
QoQ-57.0%
5Y CAGR-23.8%
10Y CAGR-7.8%

MacroGenics, Inc. held $49.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
64M
YoY+1.0%
QoQ+0.3%
5Y CAGR+0.9%
10Y CAGR+6.3%

MacroGenics, Inc. had 64M shares outstanding in Q3 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-79.8%
YoY-104.9pp
QoQ-125.3pp
5Y change-61.7pp
10Y change-68.5pp

MacroGenics, Inc.'s quarterly ROE was -79.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 104.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 125.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$30.6M
YoY-6.4%
QoQ-21.1%
5Y CAGR-9.3%

MacroGenics, Inc. invested $30.6M in research and development in Q3 2026. This represents a decrease of 6.4% from the same quarter a year earlier. Against the prior quarter it is down 21.1%.

Capital Expenditures
$72K
YoY-83.1%
QoQ-91.1%
5Y CAGR-49.2%
10Y CAGR-28.2%

MacroGenics, Inc. invested $72K in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 83.1% from the same quarter a year earlier. Against the prior quarter it is down 91.1%.

Share Buybacks

Not reported for Q3 2026.

MGNX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$18.7M-64.8%$32.8M+378.0%$20.8M+57.5%$56.6M+192.5%$53.0M-52.1%$6.9M-36.4%$13.2M+44.9%$19.4M+80.5%
Cost of RevenueN/AN/AN/AN/AN/AN/AN/A$233K
Gross ProfitN/AN/AN/AN/AN/AN/AN/A$19.1M
R&D Expenses$30.6M-6.4%$38.8M-4.9%$35.0M-11.9%$34.0M-12.6%$32.7M-19.3%$40.8M-21.1%$39.7M-13.8%$38.9M-17.9%
SG&A Expenses$8.4M-15.6%$7.9M-15.0%$9.7M-9.4%$9.2M-66.8%$9.9M-29.8%$9.3M-35.5%$10.7M-27.1%$27.8M+121.4%
Operating Income-$20.3M-295.4%-$13.9Mn/m-$33.4Mn/m-$5.6Mn/m$10.4M-80.8%-$43.2Mn/m-$42.6Mn/m-$52.8Mn/m
EBITDA-$20.1M-265.1%-$13.1Mn/m-$31.8Mn/m-$3.9Mn/m$12.2M-78.3%-$41.3Mn/m-$40.9Mn/m-$50.8Mn/m
Interest Expense$4.1M+22.2%$4.4M+448.1%$4.9M+5272.5%$4.3M$3.3Mn/m$802K+13266.7%$91K-92.0%N/A
Income Tax$0n/m$0-100.0%N/AN/A$0n/m$105Kn/mN/A$944K
Net Income-$20.1M-219.3%$19.5Mn/m-$36.8Mn/m-$14.2Mn/m$16.8M-70.1%-$36.3Mn/m-$41.0Mn/m-$15.4Mn/m
EPS (Basic)-$0.32-218.5%$0.31n/m-$0.58n/m-$0.22n/m$0.27-70.0%-$0.57n/m-$0.65n/m-$0.25n/m
EPS (Diluted)-$0.32-218.5%$0.31n/m-$0.58n/m-$0.22n/m$0.27-70.0%-$0.57n/m-$0.65n/m-$0.25n/m
Diluted Shares (Avg)64M+0.7%64M+0.7%63M+0.8%N/A63M+0.7%63M+0.8%63M+1.1%N/A

MGNX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$318.7M+17.7%$345.4M+40.7%$217.9M-3.0%$256.8M-1.8%$270.8M+2.4%$245.4M+22.0%$224.6M-9.6%$261.7M-12.3%
Current Assets$295.1M+27.1%$321.7M+57.0%$182.5M+0.2%$219.9M+1.1%$232.1M+4.5%$204.9M+30.6%$182.1M-10.1%$217.5M-13.5%
Cash & Equivalents$49.0M-38.8%$113.9M-12.8%$66.5M-54.3%$57.2M-68.7%$80.1M-55.4%$130.7M+55.7%$145.6M+81.2%$182.8M+81.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
InventoryN/AN/A$9.5M+0.8%$7.9Mn/m$8.8M+169.7%$9.3M+731.8%$9.4M+655.3%$0-100.0%
Accounts Receivable$435K-99.4%$24.6M+96.3%$10.4M-1.1%$427K-90.1%$69.2M+691.2%$12.5M+102.4%$10.5M+46.0%$4.3M-58.4%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$293.5M+44.1%$302.5M+52.2%$196.7M+35.2%$201.3M+38.2%$203.8M+41.1%$198.8M+38.7%$145.4M+2.3%$145.6M-0.1%
Current Liabilities$107.2M+141.1%$108.8M+179.0%$95.9M+73.0%$43.1M-22.4%$44.5M-25.0%$39.0M-32.6%$55.4M-0.6%$55.5M-1.0%
Non-Current Liabilities$186.3M+17.0%$193.7M+21.2%$100.7M+11.9%$158.1M+75.6%$159.3M+87.1%$159.8M+87.1%$90.0M+4.2%$90.1M+0.4%
Total Equity$25.2M-62.5%$42.9M-8.0%$21.2M-73.2%$55.6M-52.1%$67.0M-44.2%$46.6M-19.4%$79.1M-25.5%$116.1M-24.0%
Retained Earnings-$1.3Bn/m-$1.3Bn/m-$1.3Bn/m-$1.2Bn/m-$1.2Bn/m-$1.2Bn/m-$1.2Bn/m-$1.2Bn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

MGNX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$6.3Mn/m-$40.7Mn/m-$35.8Mn/m$43.0Mn/m-$30.2M-150.2%-$47.0Mn/m-$46.9Mn/m-$38.4Mn/m
Depreciation & Amortization$199K-88.9%$708K-62.9%$1.7M-4.7%$1.7M-17.0%$1.8M-2.5%$1.9M+5.3%$1.8M-3.8%$2.1M+8.1%
Stock-Based Compensation$2.1M-42.0%$2.0M-46.5%$2.6M-39.7%N/A$3.5M-40.6%$3.7M-44.5%$4.4M-21.0%N/A
Capital Expenditures$72K-83.1%$806K+12.7%$344K-35.0%$244K-60.6%$426K-28.0%$715K-30.9%$529K-63.7%$620K0.0%
Free Cash Flow-$6.4Mn/m-$41.6Mn/m-$36.2Mn/m$42.8Mn/m-$30.6M-151.4%-$47.7Mn/m-$47.4Mn/m-$39.0Mn/m
Investing Cash Flow-$59.1Mn/m$28.0Mn/m$45.3M+357.7%-$66.0M-259.1%-$20.4M-157.2%-$37.6M-179.3%$9.9M-60.1%$41.5M+6.8%
Financing Cash Flow$590Kn/m$60.2M-13.7%-$207Kn/m$57K-63.2%$0n/m$69.7M+11058.2%-$282K-213.7%$155K-43.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MGNX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

MGNX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross MarginN/AN/AN/AN/AN/AN/AN/A98.8%
Operating Margin-108.8%-42.2%-161.0%-10.0%19.6%-29.3pp-629.3%-323.1%-273.0%
Net Margin-107.5%59.4%-177.0%-25.0%+54.7pp31.7%-19.1pp-527.7%-311.1%-79.7%
Return on Equity-79.8%-104.9pp45.5%+123.3pp-173.5%-121.6pp-25.5%-12.2pp25.1%-21.8pp-77.8%+18.5pp-51.9%-2.7pp-13.3%+16.9pp
Return on Assets-6.3%-12.5pp5.7%+20.4pp-16.9%+1.4pp-5.5%+0.4pp6.2%-15.1pp-14.8%+12.9pp-18.3%+2.7pp-5.9%+9.6pp
Current Ratio2.75-2.5x2.96-2.3x1.90-1.4x5.10+1.2x5.22+1.5x5.26+2.5x3.28-0.3x3.92-0.6x
Liabilities-to-Equity11.67+8.6x7.06+2.8x9.28+7.4x3.62+2.4x3.04+1.8x4.26+1.8x1.84+0.5x1.25+0.3x
Asset Turnover0.06-0.1x0.10+0.1x0.100.0x0.22+0.1x0.20-0.2x0.030.0x0.060.0x0.070.0x
FCF Margin-34.3%+23.5pp-126.6%-174.0%75.6%-57.8%-111.6pp-694.4%-359.5%-201.7%

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
MacroGenics, Inc. MGNX FY2025 $149.5M -$74.6M -49.9% $125.3M 59/100
Compass Therapeutics, Inc. CMPX FY2025 $0 -$66.5M N/A $123.9M —
ALX Oncology Holdings Inc. ALXO FY2025 N/A -$101.7M N/A $137.0M —
Adagene Inc. ADAG FY2025 $7.7M -$17.6M N/A $118.2M 65/100
Zentalis Pharmaceuticals, Inc. ZNTL FY2025 $0 -$137.1M N/A $133.6M —
PolyPid Ltd. PYPD FY2025 N/A -$34.2M N/A $129.3M —

Frequently Asked Questions

MacroGenics, Inc. (MGNX) reported $149.5M in total revenue for fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

MacroGenics, Inc. (MGNX) revenue declined by 0.3% year-over-year, from $150.0M to $149.5M in fiscal year 2025.

No, MacroGenics, Inc. (MGNX) reported a net loss of $51.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $74.6M, with a net profit margin of -49.9%.

MacroGenics, Inc. (MGNX) reported diluted earnings per share of -$1.18 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MacroGenics, Inc. (MGNX) had EBITDA of -$65.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

MacroGenics, Inc. (MGNX) had an operating margin of -48.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

MacroGenics, Inc. (MGNX) had a net profit margin of -49.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

MacroGenics, Inc. (MGNX) has a return on equity of -134.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

MacroGenics, Inc. (MGNX) recorded an outflow of $83.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

MacroGenics, Inc. (MGNX) recorded an outflow of $81.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

MacroGenics, Inc. (MGNX) had $256.8M in total assets as of fiscal year 2025, including both current and long-term assets.

MacroGenics, Inc. (MGNX) invested $1.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

MacroGenics, Inc. (MGNX) invested $147.2M in research and development during fiscal year 2025.

MacroGenics, Inc. (MGNX) had 64M shares outstanding as of fiscal year 2025.

MacroGenics, Inc. (MGNX) had a current ratio of 5.10 as of fiscal year 2025, which is generally considered healthy.

MacroGenics, Inc. (MGNX) had a liabilities-to-equity ratio of 3.62 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

MacroGenics, Inc. (MGNX) had a return on assets of -29.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

MacroGenics, Inc. (MGNX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $125.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MacroGenics, Inc. (MGNX) trades at 1.0x sales, its market capitalization divided by $128.9M revenue, trailing 12 months to September 30, 2026. The market capitalization is $125.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, MacroGenics, Inc. (MGNX) held $57.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $81.0M over that year. Dividing the one by the other, the reported balance equals about 8 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

MacroGenics, Inc. (MGNX) has an Altman Z-Score of -5.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

MacroGenics, Inc. (MGNX) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

MacroGenics, Inc. (MGNX) reported a net loss of $74.6M while operations used $81.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

MacroGenics, Inc. (MGNX) reported an operating loss of $72.8M against $8.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

MacroGenics, Inc. (MGNX) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top